FDA hands down label expansions for Genentech and BioMarin drugs in cancer, dwarfism

Even younger pediatric patients with solid tumors or short-limbed dwarfism will now have access to treatment after the FDA approved label expansions late Friday for drugs by Genentech and BioMarin.

California-based BioMarin said that the FDA had approved a supplemental NDA for its drug Voxzogo, expanding…
Click here to view original post